Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
At a glance
Conditions
NCT03202303
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Montefiore Medical Center
The Bronx, New Yorkstudy coordinator listed
Recruiting
New York University (NYU) Langone
New York, New Yorkno site contact published
Completed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Eric Hollander, MD · PRINCIPAL_INVESTIGATOR · Montefiore Medical Center/Albert Einstein College of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Aberrant Behavior Checklist-Irritability (ABC-I) SubscaleChange from Baseline to Week 12 (Change over 12 weeks)
Change in aberrant behavior from baseline will be assessed using the irritability subscale of the ABC. The ABC is an informative rating instrument that was empirically derived by principal component analysis to measure behavior in those with developmental disability and autism spectrum disorder (ASD). The ABC-I will be completed by any adult who knows the patient well, such as a parent/caregiver. The ABC-I subscale consists of 15 items that address the presence of aggression, tantrums, and/or self-injury. Scores for each item on the subscale range from 0 (no problem at all) to 3 (problem is severe in degree), yielding an overall possible score for the subscale from 0-45, such that higher scores are indicative of increased severity of irritability. Scores will be summarized by study arm using basic descriptive statistics.